Tandem Diabetes Care (TNDM) Net Cash Flow (2013 - 2026)

Tandem Diabetes Care's Net Cash Flow history runs 14 years deep, the most recent figure standing at $89.8 million for Q1 2026.

• Quarterly Net Cash Flow rose 751.43% year-over-year to $89.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123.3 million (up 2470.0% YoY) and the FY2025 annual result came in at $19.8 million, up 117.21% from the prior year.
• Net Cash Flow was $89.8 million for Q1 2026 at Tandem Diabetes Care, up from -$2.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $89.8 million in Q1 2026 and bottomed at -$50.4 million in Q3 2023.
• A 5-year average of $6.2 million and a median of $3.3 million in 2023 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 1051.86% in 2025, while the deepest fall reached 2680.52% in 2025.
• Tandem Diabetes Care's Net Cash Flow stood at $47.7 million in 2022, then plunged by 144.41% to -$21.2 million in 2023, then surged by 185.11% to $18.0 million in 2024, then slumped by 114.33% to -$2.6 million in 2025, then surged by 3575.3% to $89.8 million in 2026.
• Business Quant data shows TNDM's Net Cash Flow at $89.8 million in Q1 2026, -$2.6 million in Q4 2025, and $27.2 million in Q3 2025.